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100 Proteins in the
athogenesis of Kawasaki Disease*
ane C. Burns, MD
a Jolla, California
awasaki disease (KD) is an acute, self-limited vasculitis of
nfants and children, and its successful treatment depends
n timely diagnosis. This vasculitis of unknown etiology,
hich is now the most common form of acquired heart
isease in children in the U.S. and Japan (1,2), presents with
linical signs that include fever, rash, conjunctival injection,
dema and erythema of the extremities, and oropharyngeal
rythema (3). Although the acute illness is self-limited, one
n four untreated children will develop permanent coronary
rtery damage with aneurysms or ectasia as a consequence of
he vasculitis (4). The acute inflammation can be abrogated
n the majority of patients with a single dose of intravenous
mmunoglobulin (IVIG) plus high-dose aspirin, which
educes the aneurysm rate to 3% to 5% if administered
ithin the first 10 days after fever onset (5). Unfortunately,
ithout a specific laboratory test, diagnosis of KD relies on
he recognition of the clinical signs, which may appear and
isappear over a period of many days. Thus, patients
ontinue to be misdiagnosed and suffer preventable morbid-
ty and mortality because of failure to recognize the condi-
ion and to administer therapy in a timely manner.
See page 1257
Although the combination of IVIG and aspirin therapy is
ighly effective, 10% to 15% of patients will be refractory to
his treatment regimen and will have persistent fever as a
anifestation of ongoing inflammation (6). These patients
re at highest risk for the development of coronary artery
amage. Potential new therapeutic approaches with anti-
umor necrosis factor-alpha monoclonal antibodies are be-
ng tested in clinical trials in KD patients (7). Such new
herapies may provide the clinician with an expanded
rmamentarium and make the early identification of pa-
ients at risk for failure to respond to IVIG more relevant.
Transthoracic echocardiography is used to classify pa-
ients as having normal, dilated, or aneurismal coronary
rteries (8). The long-term sequelae of the coronary artery
neurysms include ischemic heart disease and myocardial
nfarction. Several scoring systems have been devised to
dentify patients at highest risk for development of coronary
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.h
From the Division of Allergy, Immunology, and Rheumatology, Department of
ediatrics, UCSD School of Medicine, La Jolla, California.rtery aneurysms, but none have been validated in prospective
tudies in non-Asian patients (9). Patients at highest risk for
oronary artery damage may be candidates for more aggres-
ive antiplatelet and anti-inflammatory therapy. Thus, being
ble to predict both failure to respond to IVIG and
ncreased risk of aneurysms would have important therapeu-
ic implications for these patients.
In the absence of knowing the etiologic agent or agents
or KD, biomarker discovery has been an active area of
nvestigation. The goals have been to identify proteins in the
lood or urine that would help to differentiate KD from
ther childhood rash/fever illnesses and to predict both
esponse to IVIG therapy and coronary artery damage. In
he paper by Hirono et al. (10) in this issue of the Journal,
calcium-binding proteins in the S-100 family, (MRP)-8
nd MRP-14 (e.g., S100A8 and A9) were tested as poten-
ial biomarkers for KD and coronary artery sequelae. These
roteins form heterodimers and are secreted by neutrophils
nd monocytes in response to inflammatory signaling cas-
ades (Fig. 1). The MRP8/MRP14 heterodimer binds to
icrovascular endothelial cells and may participate in the
enesis of a proinflammatory and prothrombotic state dur-
ng systemic vasculitis (11,12). Specifically, these proteins
egulate adhesion of neutrophils and monocytes to endo-
helial cells and are implicated in their transmigration into
he vessel wall (13). Serum levels of the heterodimer
RP8/MRP14 correlate with disease activity in conditions
haracterized by systemic inflammation, including juvenile
heumatoid arthritis (14). Another member of the S100
amily, S100A12, is also released by neutrophils and mono-
ytes, binds to the receptor for advanced glycation end
roducts (RAGE) on endothelial cells and leukocytes, and
nduces cell activation and cytokine production through the
uclear factor-kappa-B signaling pathway (15,16). Tran-
cript and protein levels of all 3 of these S100 proteins are
ncreased in circulating leukocytes and in serum during the
cute phase of KD (12,17–20).
In the new study reported, the authors (10) measured
evels of MRP8/MRP14 in serum, mRNA levels in circu-
ating neutrophils and monocytes, and the presence of the
eterodimer bound to circulating, shed endothelial cells
uring the acute and convalescent stages of KD. As in
revious studies, serum levels of MRP8/MRP14 were
arkedly elevated in KD patients compared with healthy
ontrols. Unfortunately, febrile controls with non-KD rash/
ever illnesses were not included, so no conclusion can be
rawn regarding the possibility of MRP8/MRP14 het-
rodimers as biomarkers for KD. Of the 61 KD patients, 16
26.2%) were IVIG nonresponders. Although patients who
ad a response to IVIG had a clear and progressive decrease
n heterodimer levels after IVIG administration, patients
ho had persistent or recrudescent fevers had no coherent
attern of heterodimer decrease, and levels actually in-
reased in some patients. These nonresponder patients also
ad an increase in granulocyte mRNA levels for MRP8 and
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Editorial Comment September 19, 2006:1265–7RP14 at 2 weeks after IVIG infusion. Elevated levels of
eterodimer in acute KD patients before therapy followed
y markedly decreased levels after IVIG infusion have also
een reported by other groups (12,17). Abe et al. (17) used
icroarray and kinetic polymerase chain reaction to quan-
ify transcripts of MRP8 and MRP14 and measured het-
igure 1. Proposed role of S100 proteins (myeloid-related protein [MRP]-
, MRP-14, and S100A12) in the genesis and maintenance of the vasculitis
n Kawasaki disease. (Top) Tumor necrosis factor (TNF)-alpha and other
roinflammatory cytokines activate endothelium and lead to expression of
arboxylated N-glycans. Activated neutrophils and monocytes secrete
RP-8/MRP-14 heterodimers, which bind to the carboxylated N-glycans
nd heparin sulfate on the endothelial cell surface. Leukocytes also secrete
100A12, which binds to the receptor for advanced glycation end products
RAGE) expressed on endothelial cells, lymphocytes, and macrophages.
his receptor signals through the nuclear factor-kappa-B pathway and
nduces expression of many proinflammatory molecules. (Bottom) The net
esult of S100 protein binding is platelet aggregation and adherence to
ndothelium, increased expression of vascular cell adhesion molecule-1 and
ntercellular adhesion molecule-1, adhesion of neutrophils and monocytes,
oosening of endothelial cell junctions, and trafficking of inflammatory cells
cross the endothelial cell barrier. Illustration by Rob Flewell.rodimer levels in the plasma of KD patients and febrileontrols. They found a reduction in peripheral blood mono-
uclear cell and monocyte transcript abundance as well as
lasma levels of MRP8 and MRP14 after IVIG treatment.
hey also noted persistently high levels of heterodimer in
he plasma of four KD patients in whom coronary artery
neurysms developed. Ebihara et al. (19), using kinetic
olymerase chain reaction in paired acute and convalescent
hole-blood samples from 10 KD patients, also reported
levated pretreatment transcript levels of these S100 pro-
eins. Viemann et al. (12) found the same rapid decrease in
eterodimer levels after IVIG infusion and used immuno-
istochemistry to demonstrate MRP8/MRP14-positive
eutrophils adherent to the endothelium of myocardial
essels from three KD autopsies. This group also showed
R8/MR14 heterodimers bound to the endothelial cells.
his is consistent with the finding by Hirono et al. (10) of
igh numbers of circulating shed endothelial cells with
ound MRP8/MRP14 in patients with coronary artery
bnormalities at 2 weeks after treatment. In vitro experi-
ents have shown that human microvascular endothelial
ells incubated with purified MRP8/MRP14 heterodimers
pregulate expression levels of genes involved in platelet
ggregation and inflammation and downregulate expression
f genes involved in endothelial integrity (12). Taken
ogether, these observations support the hypothesis that
RP8/MRP14 heterodimers participate directly in the
athogenesis of the coronary artery vasculitis in KD and
ontribute to endothelial cell damage and transmigration of
eukocytes into the arterial wall.
Unfortunately, elevated numbers of heterodimer-positive
irculating endothelial cells cannot be used to predict
oronary artery damage because pretreatment levels were
ow and the increase in circulating levels coincided with the
ppearance of coronary artery dilatation by echocardiogram.
lthough MRP8/MRP14 heterodimer levels will not help
redict responsiveness to IVIG therapy or the development
f coronary artery lesions, these proteins are likely to be
mportant in disease pathogenesis and further investigation
nto their role in promoting inflammation and endothelial
ell damage in KD is warranted.
eprint requests and correspondence: Dr. Jane C. Burns, Divi-
ion of Allergy, Immunology, and Rheumatology, Department of
ediatrics, UCSD School of Medicine, 9500 Gilman Drive, La
olla, California 92093-0830. E-mail: jcburns@ucsd.edu.
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